A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients wi...
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
About this item
Full title
Author / Creator
Zuo, Bangyou , Yang, Xiaobo , Yang, Xu , Bian, Jin , Long, Junyu , Wang, Dongxu , Ning, Cong , Wang, Yanyu , Xun, Ziyu , Wang, Yunchao , Lu, Xin , Mao, Yilei , Sang, Xinting and Zhao, Haitao
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Background
Anti-PD-1 antibodies plus lenvatinib therapeutic regimens have demonstrated a relatively high antitumor response in many solid cancers; however, the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer (GBC) has not been reported.
Methods
Advanced GBC patients who received anti...
Alternative Titles
Full title
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991186
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10991186
Other Identifiers
ISSN
0340-7004
E-ISSN
1432-0851
DOI
10.1007/s00262-021-03121-0
